DCGI permits emergency use of Cowovax vaccine in children aged 7-11 – News18 English

New Delhi: The COVID-19 vaccine of the Drugs Controller General of India (DCGI) Serum Institute has approved Covovax for emergency use in children aged 7 to 11 years. The approval of the DCGI comes after a panel of experts from CSDCO’s COVID-19 recommended Emergency Use Authorization for Covovax for 7- to 11-year-olds last week. Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), has applied for the DCGI on March 16, official sources said.

Approval for Covovax

The SEC discussed SII’s EUA application last week. Covovax recommends emergency use authorization for children aged 7 to 11 years. At its last meeting in April, the panel of experts sought more data from the Pune-based firm on the application. DCGI approved Covovax on December 28 for restrictive use in emergency situations for adults.

A nationwide vaccine campaign

The country began vaccinating children aged 12-14 years from March 16. A nationwide vaccine campaign was launched on January 16 last year. In the first phase, health workers were given injections. The vaccine for frontline workers started from February 2 last year.

Also Read: Disease X Fear Rises; Experts warn about an unknown epidemic

The next phase of the COVID-19 vaccination began on March 1 last year for those aged 60 and over. India started vaccinating all people over the age of 45 from April 1 last year. Last year, the government decided to expand its vaccine campaign by allowing everyone over the age of 18 to be vaccinated against viral disease. The next phase of vaccination was launched from January 3 for adolescents aged 15-18 years.

India started administering precautionary doses of vaccines to health and frontline workers and those aged 60 and above with comorbidities from January 10. Precautionary doses of Covid-19 vaccines for all age groups above 18 years began at private vaccination centers from April 10.

Omicron-specific Kovid boosters

A panel of US medical experts called for omicron-specific boosters this autumn, as there is an increased demand for covid vaccines on an ongoing seasonal basis for influenza. A combined committee of the Food and Drug Administration (FDA) voted in favor of 19 and against two measures a day after reviewing available data, including future waves and initial results from vaccine manufacturers. Peter Marks, a senior FDA scientist, summed up the complexity of the problem before a panel of experts: predicting the future course of the virus, which often denies the future and transforms faster than the flu.

Read News 18 Kannada before breaking news. Get Daily News, Live News Update Believer News 18 Kannada


The Ultimate Managed Hosting Platform

Most Popular

Most Popular